Search

Displaying results 5411 - 5420 of 10000 in total
  1. Drug

    Piclidenoson

    go.drugbank.com/drugs/DB05511
    Investigational

    Its novel mechanism of action relies on antagonism of adenoside A3 receptors. CF101 is supplied as an oral drug and has an excellent safety profile. … It is also being considered for the treatment of other autoimmune-inflammatory disorders, such as Crohn's disease, psorasis and dry eye syndrome.

  2. Drug

    Telratolimod

    go.drugbank.com/drugs/DB19590
    Investigational

    Telratolimod has a monoisotopic molecular weight of 593.47 Da. … Telratolimod is under investigation in clinical trial NCT06680479 (Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

  3. Drug

    Rezivertinib

    go.drugbank.com/drugs/DB21471
    Investigational

    Rezivertinib has a monoisotopic molecular weight of 486.24 Da. … Rezivertinib is under investigation in clinical trial NCT06955325 (Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations).

  4. Drug

    Opnurasib

    go.drugbank.com/drugs/DB21583
    Investigational

    Opnurasib has a monoisotopic molecular weight of 525.2 Da. … Opnurasib is under investigation in clinical trial NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  5. Drug

    AI-850

    go.drugbank.com/drugs/DB05842
    Experimental

    AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.

  6. Drug

    NOX-700

    go.drugbank.com/drugs/DB05464
    Experimental

    In animal studies, NOX-700 lowered serum glucose, improved glucose tolerance, and reduced the percentage of total glycated hemoglobin. … NOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes).

  7. Drug

    DDP733

    go.drugbank.com/drugs/DB05049
    Investigational

    Preclinical studies of DDP733 established the compound’s prokinetic properties (the ability to promote the motility of the GI tract). … It is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system.

  8. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    It is developed by MedImmune for the treatment of Allergic Rhinitis. … Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development.

  9. Drug

    Vofatamab

    go.drugbank.com/drugs/DB14781
    Investigational

    Vofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma).

  10. Drug

    Inupadenant

    go.drugbank.com/drugs/DB19129
    Investigational

    Inupadenant is under investigation in clinical trial NCT05060432 (Study of EOS-448 With Standard of Care And/or Investigational Therapies in Participants With Advanced Solid Tumors).